---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-022182"
form_type: "8-K"
ticker: "CLSDQ"
cik: "0001539029"
company_name: "Clearside Biomedical, Inc."
filed_at: "2023-02-02T23:59:59+00:00"
generated_at: "2026-06-20T02:18:51.772869+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Positive OASIS extension results: 67% of wet AMD patients went ≥6 months without retreatment; cash $48.3M

## Summary
- 67% of extension participants (8/12) went ≥6 months without additional treatment; 50% went >6 months.
- Treatment burden reduced 77-85% vs. average monthly injections prior to CLS-AX administration.
- No serious adverse events, inflammation, vasculitis, or vascular occlusion; excellent safety profile.
- Planned initiation of Phase 2b ODYSSEY trial in Q1 2023 with primary endpoint readout mid-2024.
- Preliminary unaudited cash and cash equivalents of $48.3M as of December 31, 2022.

## SEC filing metadata
- accession: 0001193125-23-022182
- form_type: 8-K
- ticker: CLSDQ
- cik: 0001539029
- company_name: Clearside Biomedical, Inc.
- filed_at: 2023-02-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1539029/000119312523022182/0001193125-23-022182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1539029/000119312523022182/d425744d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-022182
- JSON: https://secwatch.observer/filing/0001193125-23-022182.json
- Plain text: https://secwatch.observer/filing/0001193125-23-022182.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.